Colman RE, et al. - Researchers assessed whole-genome sequencing (WGS) and targeted next-generation sequencing (NGS) for tuberculosis (TB) on both the new iSeq100 and the widely used MiSeq (both manufactured by Illumina) and compared sequencing performance, costs, and usability. Findings revealed that the MiSeq and iSeq100 have listed instrument prices of $99,000 USD and $19,900 USD. With comparable accuracy to the MiSeq, the iSeq100 instrument can run existing TB WGS and targeted NGS library preparations. The iSeq100 has reduced hands-on sequencing workflow time and can deliver results of sequencing within 24 hours. Lower capital and maintenance costs and lower-throughput capabilities also give the iSeq100 an advantage over MiSeq in individualized care settings. This is less the case in high-throughput settings (like reference laboratories) where sample batching can be optimized to minimize costs at the expense of complexity and time in the workflow.